MercadoLibre (NasdaqGS:MELI) 2025 Conference September 10, 2025 12:30 PM ET Company ParticipantsMartín de los Santos - EVP & CFOConference Call ParticipantsIrma Sgarz - Managing Director & Equity Research Analyst - Latam Retail & Consumer GoodsIrma SgarzWelcome to the MercadoLibre Fireside Chat at the Goldman Sachs Communicopia and Technology Conference. I'm pleased to welcome here CFO Martín de los Santos, CFO of MercadoLibre. My name is Irma Skarts. I cover the Latin America e-commerce and retail sector f ...

ProMIS Neurosciences (NasdaqCM:PMN) FY Conference September 10, 2025 12:30 PM ET Speaker0Good afternoon, everyone. Thank you for joining us for our next session at the H. C. Wainwright Global Investment Conference. My name is Joshua Corson, and I'm an equity research associate at H.C. Wainwright. For our next session, I would like to introduce our presenter, Neil Warmah, who is the CEO of Promis Neurosciences. Floor is yours.Speaker1Thanks very much. I appreciate it. Thanks everybody for joining this aftern ...

Diebold Nixdorf Conference Call Summary Company Overview - **Company**: Diebold Nixdorf (NYSE: DBD) - **Core Markets**: Banking and Retail [6][7] - **Opportunities**: Focus on branch automation in banking and expansion in the U.S. retail market [6][8] Banking Segment Insights - **Branch Efficiency**: Banks are seeking to improve branch efficiency as running a branch network accounts for 60% of their expenses [7][23] - **Solutions Offered**: - Recycling ATMs and teller cash recyclers to enhance cash management [7][24] - Software solutions that integrate physical branches with digital channels [25] - **Productivity Gains**: Recent implementations have improved teller productivity by 50% [24] Retail Segment Strategy - **Market Position**: Strong presence in Europe, aiming to expand in the U.S. [7][8] - **Self-Checkout Leadership**: Achieved number one position in self-checkout in Europe, targeting U.S. market expansion [26][39] - **AI-Driven Solutions**: Focus on reducing theft at checkout through AI and computer vision technologies [28][30] Financial Performance and Projections - **Free Cash Flow**: Positive free cash flow for three consecutive quarters, with a target of $800 million by 2027 [10][12] - **Revenue Growth**: Projected mid-single-digit growth from low single digits, with a target of 4% to 6% top-line growth by 2027 [12][42] - **Backlog**: Current backlog stands at $980 million, providing strong visibility into future revenue [46] Operational Improvements - **Margin Growth**: Product margins improved from low teens to mid to high 20s over two years [18][48] - **Lean Manufacturing**: Continuous improvement initiatives have led to significant enhancements in quality and delivery times [49][50] Capital Allocation and Shareholder Returns - **Debt Management**: Aiming for a 1.5x net debt leverage ratio, maintaining a strong balance sheet [13] - **Share Buyback Program**: Announced a $100 million buyback program, with $38 million already executed [13][14] Risk Factors and Market Conditions - **Tariff Exposure**: Estimated impact of $5 million to $10 million from tariffs, mitigated by local-to-local manufacturing strategies [52][53] - **ATM Market Dynamics**: The ATM market is stable with a slight growth trend, primarily driven by replacement rather than new installations [32] Key Differentiators - **Comprehensive Solutions**: Integration of hardware, software, and services to enhance banking and retail operations [25][31] - **Customer-Centric Approach**: Focus on understanding customer needs and providing tailored solutions [39][40] Conclusion Diebold Nixdorf is positioned for growth in both banking and retail sectors, leveraging technology and operational efficiencies to enhance profitability and shareholder value. The company is committed to executing its strategic initiatives while maintaining a strong focus on free cash flow generation and capital allocation.

Remitly Global (NasdaqGS:RELY) 2025 Conference September 10, 2025 12:30 PM ET Company ParticipantsMatt Oppenheimer - CEO and Co-founderTien-Tsin Huang - Managing DirectorVikas Mehta - CFOTien-Tsin HuangAll right. We are going to get started. Kicking off the day, we've got Matt Oppenheimer, CEO and co-founder of Remitly, as well as Vikas, who's made a surprise appearance. Thank you for joining us today, Vikas.Vikas MehtaThank you.Tien-Tsin HuangAll right. I wanted to just kinda kick it off high level with a ...

Alnylam Pharmaceuticals (NasdaqGS:ALNY) FY Conference September 10, 2025 12:20 PM ET Company ParticipantsJeff Poulton - CFOMichael Ulz - Executive Director - Biotechnology Equity ResearchMichael UlzAll right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Gold, one of the biotech analysts here, and it's my pleasure to introduce Jeff Poulton, CFO of Alnylam Pharmaceuticals. Before we get started, I just need to read a quick disclosure. For imp ...

Pacific Biosciences of California (NasdaqGS:PACB) FY Conference September 10, 2025 12:20 PM ET Speaker0My name is Yuko Oku, and I'm on the Life Science Tools and Diagnostics team here at Morgan Stanley. Before we begin, for important disclosures, please see Morgan Stanley Research Disclosure website at www.morganstanley.comresearchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales rep. With that, it's my pleasure to host PacBio. And speaking on behalf of the company, we ha ...

Summary of Certara FY Conference Call - September 10, 2025 Company Overview - **Company**: Certara (NasdaqGS:CERT) - **Industry**: Health Technology and Biosimulation Key Points and Arguments Growth Strategy - Certara is focused on accelerating organic growth despite a subdued market environment, targeting mid-single-digit growth rates [4][5] - Investments in sales, marketing, and R&D are being made to enhance the commercial organization and software platforms [4][5] - New software enhancements, including Certara IQ (AI-enabled software for Quantitative Systems Pharmacology, QSP), are expected to drive growth [5][10] R&D and Product Development - Certara is addressing critical pain points in drug development, particularly the high failure rates of drug trials, by enhancing software capabilities [7] - The company has launched Certara Cloud, which has seen rapid adoption, particularly among large biopharma customers [11][12] - The tiered customer structure includes: - **Tier 1**: Large biopharma (50% of revenue) - **Tier 2**: Mid-sized companies (20% of revenue) - **Tier 3**: Biotechs (30% of revenue) [14][15] Market Dynamics - The funding environment for tier three customers remains challenging, but Certara has successfully targeted biotechs with funding potential [13][15] - The FDA's directive to shift away from animal testing is seen as a tailwind for Certara, enhancing customer discussions and driving demand for SIMCYP and QSP [24][34] Financial Performance - Certara expects an adjusted EBITDA margin of 30-32% for the year, consistent with previous performance [20] - The company is on track to meet its full-year plan despite some timing issues in software bookings for tier one customers [16][17] AI and Technology Integration - The acquisition of Vyasa has enabled Certara to integrate AI technology into its workflow and product offerings [25][26] - The co-author tool for regulatory writing has demonstrated a 40% efficiency improvement, appealing to regulatory customers [27] M&A and Strategic Review - Certara is actively engaged in a strategic review of its regulatory business, which has returned to growth with a 20-30% adjusted EBITDA margin [43][44] - The company is focused on software acquisitions to shift its revenue mix from services to software, aiming for a balanced profitability profile [45][46] Capital Allocation - Certara prioritizes R&D investments while also considering M&A opportunities and share buybacks, having authorized a $100 million share repurchase program [47][48] Additional Important Insights - Certara's longstanding relationship with the FDA provides a competitive advantage, as many FDA users are familiar with Certara's software [32][33] - The company is well-positioned to help biopharma clients find efficiencies across the drug development cycle, from discovery to submission [30][31] - The integration of Camaxon, a chem-informatics software company, is progressing well, with expectations to enhance margins and product offerings [40][41]

Caledonia Mining Corporation (NYSEAM:CMCL) 2025 Conference September 10, 2025 12:15 PM ET Speaker0Thank you. Good morning, everyone. It's my absolute pleasure to change tact and talk about the Caledonia story. It's a very exciting pathway and we're really excited about the future and particularly the next sort of five years ahead of us. Draw your attention to the standard disclaimer.Can read it at your leisure. I guess our formula, our strategy is very simple in terms of how we view the company and how we a ...

Enanta Pharmaceuticals (NasdaqGS:ENTA) 2025 Conference September 10, 2025 12:15 PM ET Speaker0Good afternoon, everyone. Welcome back from lunch. I'm Brian Swaney. I'm one of Baird's senior biotech analysts. I'm really happy to have with us the management team from Enanta Pharmaceuticals next.It's a company that I've followed for a long time. They have a number of pipeline programs that I think are really interesting and exciting to talk about. I'm going to have Jay Luly, the CEO, come up here and give a lit ...

Vertiv (NYSE:VRT) FY Conference Summary Company Overview - **Company**: Vertiv - **Date**: September 10, 2025 - **Key Speakers**: CEO Giordano Albertazzi, CFO David Fallon Industry Insights - **Market Demand**: Strong demand in the data center market with a reported **35% organic growth** last quarter and a **$1.2 book-to-bill ratio** [3][25] - **Pipeline Strength**: The strength of the pipeline is a critical indicator of future performance, defined as active commercial opportunities with quotes [5][6] - **Liquid Cooling**: The industry is shifting towards liquid cooling, which is expected to represent about **one-third of the total Total Addressable Market (TAM)** for data center cooling [9][10] - **CapEx Structure**: The growth in IT spending is increasing, but the physical infrastructure segment remains strong, indicating a healthy TAM for Vertiv [11][12] Key Company Strategies - **Focus on White Space**: Vertiv is increasing its presence in the white space of data centers, which is becoming a fertile ground for growth due to rising complexity in power and cooling distribution [12][14] - **Future-Proofing Infrastructure**: The company is collaborating with key players like NVIDIA to design future-proof data center infrastructures [16][19] - **Prefabrication Solutions**: Introduction of prefabricated solutions to significantly reduce fit-out time in data centers, enhancing time to revenue for customers [13][14] Growth Constraints and Capacity - **Growth Moderating Factors**: Power availability is a limiting factor in some regions, but there is no expectation of a cliff in demand. The construction nature of the data center industry also limits speed [25][26] - **Capacity Management**: Vertiv is expanding manufacturing capacity and ensuring service capacity grows in line with manufacturing to maintain operational leverage [27][29] Financial Performance - **Margins**: Gross margins faced pressure due to tariffs and operational challenges, but a recovery is projected with operating margins expected to reach **20% in Q3** and **over 23% in Q4** [33][34] - **Pricing Strategy**: The company is actively managing pricing to offset tariff impacts and is confident in maintaining a price-cost positive position moving forward [35][36] Regional Market Insights - **North America**: Strong growth with a **40% increase** in physical shipments [40] - **Europe**: Slow growth attributed to regulatory challenges, but strong pipelines and low vacancy rates in data centers suggest potential for future growth [42][43] - **Asia-Pacific**: Generally positive outlook, with specific mentions of growth opportunities in India and China [43] Conclusion - Vertiv is well-positioned in the data center market with strong growth indicators, a focus on innovative solutions, and strategic partnerships. The company is navigating challenges related to tariffs and capacity while maintaining a positive outlook for future performance.